ClinicalTrials.gg
RecruitingNCT07449130ARTEMISUpdated Aug 21, 2026

AI Assisted Screening for VHD Using Routine Chest CT Scans

An observational study in Heart Valve Diseases, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Valve Diseases with a site in China — 28 open to participants now, 30 under way, none of them phase 3. Heart Valve Diseases · China.

Planned enrollment
18th of 35
3,000 · median 3,000
Started
2026
with 6 others
Observational
35 of 69
17 open now
Primary completion
2026-11
later than 14 of 29 live
Registered
61st of 69
by date

Among the 69 studies in Heart Valve Diseases with a site in China, this one is the 18th largest by planned enrollment of the 35 observational ones that give a count, is one of 7 that started in 2026, is one of 35 observational ones, reaches primary completion later than 14 of the 29 other live ones, and was the 61st registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

28 of the 69 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Valve Diseases with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans.

The primary objective is to evaluate the model's diagnostic performance, with the sensitivity serving as the primary efficacy endpoint. Secondary endpoints will include other performance metrics such as area under the receiver operating characteristic curve (AUC), specificity, and accuracy, etc.

Read the detailed description

This is a prospective, multicenter study designed to validate a deep learning model for screening valvular heart diseases using routine, non-contrast chest computed tomography (CT) scans from individuals in any medical context within a hospital alliance.

The primary objective is to evaluate the model's diagnostic performance, with the sensitivity serving as the primary efficacy endpoint. Secondary endpoints will include other performance metrics such as area under the receiver operating characteristic curve (AUC), specificity, and accuracy, etc.

Participants from the target populations will undergo a routine non-contrast chest CT scan. The deep learning model will analyze these images in real-time. For those identified by the model as having moderate-to-severe heart valve disease, a confirmatory echocardiogram will be performed immediately. The echocardiogram results will serve as the reference standard for diagnosis. Statistical analyses will be performed to assess the model's performance against this reference, including calculating the 95% confidence interval for the AUC.

As this study only involves standard, low-radiation diagnostic imaging procedures (non-contrast CT and echocardiography) that are part of routine clinical care, it is considered to pose no additional relevant safety risks to participants. The total study duration is estimated to be 12 months.

03

Conditions studied

  • Heart Valve Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

People aged 18 and above in any medical context of hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Complete electronic health record.
  3. Non-contrast chest CT performed between Nov 1, 2025 - Nov 1, 2026 in any medical context (including physical exam, outpatient, inpatient, or emergency).
  4. AI-predicted moderate or severe valvular heart disease, or deemed to require clinical intervention, or selected negative cases from sampling verification.

Exclusion criteria

Exclusion Criteria:

  1. Poor-quality non-contrast chest CT images.
  2. Incomplete clinical records, involving severe deficiencies in critical diagnostic results, treatment records, imaging data, surgical records, medical history summaries, laboratory test results, or other essential medical information.
  3. Presence of prosthetic valve implants, including aortic valves (mechanical valves, bioprosthetic valves), mitral valves (transcatheter edge-to-edge repair, bioprosthetic valves, mechanical valves, annuloplasty rings), tricuspid valves (TEER clipping, bioprosthetic valves, mechanical valves, annuloplasty rings), pulmonary valves (bioprosthetic valves), etc.
  4. Abnormalities or conditions deemed by the investigator to warrant exclusion from the study enrollment.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Sensitivity

    Sensitivity: Measures the proportion of patients with moderate-to-severe disease that the model correctly identifies.

    Time frame: 1 year

Secondary outcomes

  1. Area Under the Receiver Operating Characteristic Curve (AUC)

    AUC for a model distinguishing valvular disease severity. The AUC value for this model would indicate how well it can correctly identify patients with moderate-to-severe disease from those with normal-to-mild disease.

    Time frame: 1 year

  2. Accuracy

    Accuracy: Measures the overall proportion of all patients that the model correctly classifies into either group.

    Time frame: 1 year

  3. Specificity

    Specificity: Measures the proportion of patients with normal-to-mild disease that the model correctly identifies.

    Time frame: 1 year

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 7 months is below that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Nov 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07449130
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 2, 2026
Primary completion
Nov 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Aug 21, 2026

Study contacts

Jian'an Wang, MD
Contact
wangjianan111@zju.edu.cn
+86-571-8778-4808

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion